Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns

August 10, 2011 By Bio-Medicine.Org

BETHESDA, Md., Aug. 10, 2011 /PRNewswire/ — Northwest
Biotherapeutics (OTC.BB: NWBO) reminded markets, in response to
recent investor concerns about Dendreon’s Provenge immune therapy,
that NWBT’s DCVax® immune therapies for a broad range of
cancers (including prostate, brain, ovarian and others) hold the
promise, based on available data to date, of being cost effective
and priced below other immune therapies while still providing
substantial profit margins for the Company and longer survival for
patients.  

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The investor concerns in the news relate to the pricing and
reimbursement of Provenge for late stage, metastatic prostate
cancer.  Provenge is priced at $93,000 for one
month
of treatment and was approved by the FDA based upon
having added 4.5 months of patient survival (to reach
overall survival of 25.9 months).  

NWBT’s DCVax® will be priced in the range of
$37,000 per year for up to 3 years of treatments.  In
NWBT’s Phase I/II multi-center clinical trial in late stage,
metastatic prostate cancer, DCVax® added 18 months of
patient survival
(to reach overall survival of 38.7 months).
 DCVax® has previously been cleared by the FDA for a
612-patient, randomized, controlled Phase III trial, although the
trial has not yet begun.  As is typical before a Phase III
trial, the manufacturing processes and product costs have already
been determined.

Linda Powers, Chairman of the NWBT Board and CEO commented that
 “It is really important that  pricing and reimbursement
concerns associated with certain immune therapies, such as
Provenge, not cause a disillusionment with all of the emerging
immune therapies for cancer. Some of these, such as DCVax®,
while at an earlier stage of development, continue to prog

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech